Japan has the world's third-largest pharma industry. Yet, for many international companies, the market has not proved easy to access. Very high barriers to entry have combined with a historically insular domestic market to limit opportunities. This is now changing. Japan's domestic market is looking increasingly at exports, and international companies are seeking opportunities to invest in and access the large, well-funded healthcare system.
Japan is enjoying its longest sustained period of growth in over a decade. An ageing population and broad access to healthcare are the driving factors. With over 100 domestic pharma companies, such a fragmented market is likely to develop into an acquisitional environment, particularly with internationals looking to enter. Demographics are shaping the Japanese pharma industry. The population has declined and aged over the last few decades due to low birth and migration rates.
Life expectancy is now 85 years.
Reva Pharma continued its 8th successive year of participation at CPHI â€“ BIG SIGHT (Tokyo). A seminar was conducted by Dr Gurpreet Sandhu (REVA PHARMA) along with Rohto Pharmaceuticals, Astellas Pharma and Pharmacopeia Commission of India. The lecture TOPIC was: PHARMA & HEALTHCARE VISION.
The session was very productive as interface between Management Heads of Japan Multinationals operating in India outlined their experiences and vision of growth. Reva Pharma also continues its committed partnership with Osaka Pharmaceutical Association (which is now re-named as KPIA â€“ Kansai Pharmaceutical Industries Association).
For more details refer: ubm.cphi.com/jp18mp/
Dr. Gurpreet Sandhu has addressed the U.S. Congress Representatives, Industry Captains, "American Association ...
Japan has the world's third-largest pharma industry. Yet, for many international companies, the market has not...
Indian Prime Minister Narendra Modi addressed the 2nd India-Korea Business summit jointly organised by The Cho...
© Copyright 2020 - All Rights Reserved Reva Pharma.